Oncology News & Perspectives

Featured Exclusive

Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. In this interview with i3 Health, Margaret von Mehren, MD, lead investigator of the INVICTUS study, on which ripretinib's recent FDA approval was based, d...

Top Oncology Stories

Friday, June 05, 2020
Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least...
Thursday, June 04, 2020
This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial...
Wednesday, June 03, 2020
In the phase 3 BOSTON trial, a team of researchers led by Meletios Dimopoulos, MD, found that selinexor/bortezomib/dexamethasone (SVd) significantly improved survival compar...
Tuesday, June 02, 2020
The FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.) in combination with bevacizumab (Avastin®, Genentech, Inc.) for patients with locally advanced unresectable o...
Monday, June 01, 2020
The FDA has approved ramucirumab (Cyramza®, Eli Lilly and Company) in combination with erlotinib for patients with previously untreated advanced non-small cell lung cancer (...

Expert Perspectives

Ripretinib (QinlockTM, Diciphera Pharmaceuticals, LLC) represents a new option for patients with advanced gastrointestinal stromal tumor (GIST) previously treated with at least three kinase inhibitors, including imatinib. In t...
This past weekend in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, John Kuruvilla, MD, presented results of the phase 3 KEYNOTE-204 trial, reporting that pembrolizumab significantly incre...
In the phase 3 BOSTON trial, a team of researchers led by Meletios Dimopoulos, MD, found that selinexor/bortezomib/dexamethasone (SVd) significantly improved survival compared with bortezomib/dexamethasone (Vd) alone in pat...
Atezolizumab (Tecentriq®, Genentech, Inc.) was recently approved by the FDA for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high expression of programmed death ligand-1 (PD-L...
In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lu...

Original Research

Pre-activity assessment data from i3 Health's nursing continuing professional development (NCPD) activity "Understanding and Optimizing CAR T-Cell Therapy for Patients With B-Cell Malignancies" has revealed significant baseline kn...
At the 67th Society of Government Service Urologists (SGSU) Kimbrough Urological Seminar, held from January 15th to 19th, 2020, in Charlotte, North Carolina, i3 Health conducted a survey of participants regarding the formats i...
Pre-activity assessment data from i3 Health's continuing medical education (CME)/continuing nursing education (CNE) activity "Optimizing the Management of Advanced Cervical Cancer With Checkpoint Inhibitor Therapy" has reveale...
Due to the increase in treatment options for castration-resistant prostate cancer (CRPC) in recent years, some confusion exists over the optimal therapeutic approach. A number of factors must be considered in CRPC treatment...
Optimal management of carcinoid syndrome in patients with neuroendocrine tumors poses a challenge, due to the fact that the primary symptoms of carcinoid syndrome are associated with more common diseases. Because timely rec...

Copyright © 2020 i3 Health. All rights reserved.